Melanoma And Other Skin Cancers

Immune Checkpoint Inhibitor Efficacy Varies by Sex

May 17, 2018

The researchers found that, compared with men treated in control groups, the pooled overall survival hazard ratio was 0.72 for male patients treated with immune checkpoint inhibitors.

Teledermatology Could Expedite Care for Suspected Skin Cancer

May 14, 2018

The researchers found that the mean time to clinical resolution was 9 days with teledermoscopy referral, compared with 35 days with usual care alone.

Chronic Aspirin Exposure Linked to Melanoma Risk in Males

May 09, 2018

After stratification by gender, a significant correlation was seen for aspirin exposure and melanoma diagnosis among males (adjusted relative risk, 1.83; 95% confidence interval, 1.22 to 2.76; P=.004), but not females (adjusted relative risk, 0.53; 95% confidence interval, 0.17 to 1.63; P=.266).

Tafinlar + Mekinist Approved for Adjuvant Tx of Melanoma With BRAF V600 Mutation

By May 01, 2018

Approval was based on COMBI-AD, an international, multi-center, randomized, double-blind, placebo-controlled trial in 870 patients with Stage III melanoma with BRAF V600E or V600K mutations, and pathologic involvement of regional lymph node(s).

Knowledge Not Tied to Addictive Tanning Behavior in Millennials

April 27, 2018

Furthermore, motivation for perceived appearance enhancement was a significant predictor of addictive tanning behavior. The correlation between narcissism and additive tanning was mediated by appearance motivation.

Adjuvant Pembrolizumab May be Beneficial in Stage III Melanoma

April 16, 2018

The researchers found that in the overall intention-to-treat population, pembrolizumab correlated with significantly longer recurrence-free survival than placebo at a median follow-up of 15 months.

Few Indoor Tanners Have Been Screened for Skin Cancer

April 05, 2018

"Few indoor tanners (ITs) have been screened for skin cancer, although skin cancer (SC) rates are higher than among non-tanners," the authors write. "It is not surprising that SC screening is associated with SC risk factors (e.g., family history of SC and age) among ITs."

USPSTF: Behavioral interventions do not reduce sunburn or skin cancer outcomes

March 22, 2018

Behavioral interventions increase sun protection behavior but do not reduce sunburn or skin cancer outcomes.

Links Between Hydrochlorothiazide and Non-Melanoma Skin CA Examined

March 22, 2018

High use of hydrochlorothiazide (≥50,000mg) was associated with basal cell carcinoma and squamous cell carcinoma.

USPSTF: Fair-Skin Youths Should be Counselled on Minimizing UV Exposure

March 21, 2018

Based on these findings, in order to reduce the risk of skin cancer, the USPSTF recommends counseling regarding minimizing exposure to ultraviolet radiation for those aged 6 months to 24 years with fair skin types (B recommendation).

High Prevalence of Sunburn in U.S. Highlights Need for Targeted Prevention

March 15, 2018

The researchers found that 34.2% of participants experienced sunburn in 2015. The prevalence was higher among younger age groups (51.2% for those aged 18 to 29 years) and in non-Hispanic whites and those with sun-sensitive skin (42.5 and 50.2%, respectively).

FDA Approves New Dosing Option for Opdivo

By March 06, 2018

This approval will provide healthcare professionals the flexibility to customize patient care.

New Scale May Help Identify Patients Addicted to Tanning

March 05, 2018

The researchers found that tanning addiction was positively associated with being female, not being in a relationship, extroversion, neuroticism, anxiety, and obsessive-compulsiveness. New Screening Tool Developed to Assess Tanning Addiction

The Skin Bacteria That Could Inhibit Melanoma Growth

March 01, 2018

Compared with mice colonized with a control S. epidermidis strain that did not produce 6-HAP, colonization of mice with a 6-HAP-producing strain reduced the incidence of ultraviolet-induced tumors. Multiple healthy human subjects had S. epidermidis strains producing 6-HAP.

Dermoscopic Criteria Accuracy Assessed in Diagnosing Melanoma in Situ

February 23, 2018

The researchers found that 25.3% of the lesions were MIS. The most frequent dermoscopic criteria for MIS were regression, atypical network, and irregular dots and/or globules (92.9, 85.5, and 50.2%, respectively).

Obese Individuals May Have Greater Metastatic Melanoma Survival Odds

February 21, 2018

The obesity-related survival benefit was seen only for patients receiving targeted therapy (hazard ratios, 0.72 and 0.6 for progression-free and overall survival, respectively) and immunotherapy (hazard ratios, 0.75 and 0.64, respectively), not for patients receiving chemotherapy.

Parental Awareness Lacking for Dangers of Indoor Tanning

February 20, 2018

Parent sex, parent indoor tanning use, and adolescents' skin reactivity were associated with perceiving high indoor tanning benefits.

Guidelines of Care Issued for Management of Skin Cancer

January 22, 2018

The guidelines address biopsy techniques and histopathologic assessment, staging of tumors, surgical and nonsurgical management, follow-up, prevention of recurrence, and advanced disease management.

Tumor Responses to PD-1 Blockade Assessed in Desmoplastic Melanoma

January 17, 2018

The percentage of PD-L1-positive cells was higher in the tumor parenchyma in desmoplastic melanomas than in non-desmoplastic melanomas (P=0.04).

HCTZ Use Linked to Increased Risk of Non-Melanoma Skin Cancer

January 08, 2018

Researchers found an inncreased risk for basal cell carcinoma, squamous cell carcinoma, with dose-response relationship.

Opdivo Approved as Adjuvant Tx for Patients With Melanoma

By December 21, 2017

The major efficacy outcome measure was RFS, defined as the time between the randomization date and the date of first recurrence (local, regional, or distant metastasis), new primary melanoma, or death from any cause, whichever occurs first.

First Dose-Escalation Study Examines Ulixertinib for Advanced Tumors

December 18, 2017

The researchers found that ulixertinib exposure was dose-proportional to the RP2D and almost completely inhibited ERK activity in whole blood.

Effectiveness of Vermilionectomy in SCC and AC of the Lower Lip Investigated

December 15, 2017

SCC was revealed accompanying AC in 14 patients in postoperative biopsy; four patients in the AC-only group had SCC in situ.

Patidegib Gets Breakthrough and Orphan Designation for Gorlin Syndrome

By November 20, 2017

Gorlin Syndrome is a rare, genetic disease characterized by mutations in the tumor suppressor gene encoding Patched1.

USPSTF Issues Draft Recommendation on Counseling to Prevent Skin Cancer

October 11, 2017

The researchers recommend that clinicians provide counseling on sun protection behaviors for anyone with fair skin aged 6 months to 24 years, including parents of young children with fair skin (B recommendation).

Can β-Blocker Use Protect Against Melanoma Recurrence?

September 29, 2017

The researchers found that the use of propranolol at the time of diagnosis was significantly inversely linked to melanoma recurrence after adjustment for known prognostic factors, with about an 80% reduction in risk for propranolol users.

BRAF, MEK Inhibitor Combo Assessed in Resected Melanoma

September 13, 2017

The researchers found that the estimated 3-year rate of relapse-free survival was 58% in the combination-therapy group and 39% in the placebo group at a median follow-up of 2.8 years.

Nivolumab vs. Ipilimumab as Adjuvant Tx in Resected Advanced Melanoma

September 12, 2017

The researchers found that the 12-month rate of recurrence-free survival was 70.5 and 60.8% in the nivolumab and ipilimumab groups, respectively, at a minimum follow-up of 18 months.

Anti-PD-1 Therapy Tied to Neurological Adverse Events

September 11, 2017

The researchers found that 2.9% of the 347 patients treated with anti-PD-1 monoclonal antibodies developed subacute onset of neurological complications.

Cemiplimab Gains Breakthrough Tx Designation for Advanced Skin Cancer

By September 08, 2017

A Phase 2, single-arm, open-label clinical trial, EMPOWER-CSCC 1, is now enrolling patients with metastatic CSCC and locally advanced and unresectable CSCC.